Navigation Links
AlphaVax Announces New Vice President of Regulatory, Quality and Clinical Operations

RESEARCH TRIANGLE PARK, N.C., Feb. 16 /PRNewswire/ -- AlphaVax announced today that it has hired Lynn Baird, PhD, as Vice President of Regulatory, Quality and Clinical Operations. In this capacity Lynn will provide leadership and strategic direction in the areas of regulatory and quality affairs and in clinical operations.

"Lynn's experience in directing successful clinical trials, developing regulatory strategy and gaining regulatory approval for clinical trials will complement our existing leadership team. We will look to Lynn to manage the regulatory affairs for in-house programs at AlphaVax as they move through clinical development, as well as coordinate and support regulatory activities of corporate partners involved with our alphavirus vector platform," said Andrew Graham, Vice President of Development at AlphaVax.

Most recently, Lynn was Sr. Vice President, Regulatory, Quality and Clinical Operations with CombinatoRx, Inc. in Cambridge, MA. Previous to that appointment, she held executive management positions for regulatory affairs and quality at Dyax, Curis and CytoTherapeutics. Lynn earned her Ph.D. in Microbiology and Immunology from Virginia Commonwealth University in Richmond, Virginia.

"We are truly delighted to attract someone of Lynn's caliber, capability and expertise. There is no doubt that she will play a significant role in our future growth and success as we advance multiple vaccine products through clinical development," said Jonathan Gelles, Chairman of AlphaVax's Board of Directors.

About AlphaVax

AlphaVax, Inc. is a North Carolina-based, clinical-stage company that uses a proprietary alphavirus vector platform technology that has proven to be highly flexible and immunogenic, and allows the same manufacturing, formulation, and delivery strategies to be applied to many different products. The company's business strategy is to maximize the potential of this platform through a mixture of in-house and partnered programs. The AlphaVax technology is currently being used to advance vaccines for influenza, cytomegalovirus, herpes simplex virus, respiratory syncytial virus, a range of cancers, HIV and a number of biodefense targets. The AlphaVax headquarters and R&D facilities are located in Research Triangle Park, and its GMP-compliant manufacturing facility is located in Lenoir, NC.

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cardinal Health Announces New Name for Spinoff Company
2. ATS Medical Announces Fourth Quarter 2008 Earnings Release Date and Conference Call
3. URAC Announces Agenda for 2009 Best Practices in Health Care Consumer Empowerment and Protection Conference
4. Hill-Rom Announces Second Quarter 2009 Dividend
5. Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million;
6. Stemedica Announces the Appointment of Riccardo Nisato, MBA, PhD as Director of Manufacturing and Clinical Business Development for Stemedica International
7. QLT announces that it is named as a defendant in an action
8. Biotel Announces Profitable Second Quarter Ended December 31, 2008
9. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2008 Financial Results Teleconference and Webcast
10. Investor Group Commends Jim Merselis for Joining Trinity Biotechs Board of Directors & Announces Conference Call Invitation
11. Cogdell Spencer Announces Dorr as President of the Southeast Region
Post Your Comments:
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... a real-time eReferral system for diagnostic imaging in the Waterloo region. Using the ... and Nuclear Medicine tests directly from their electronic medical record (EMR) without the ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug Delivery ... to integrate dose form selection in early phase drug development. The first of ... and bringing together the UK’s emerging life sciences companies, corporate partners, and investors, ...
(Date:11/26/2015)... , ... November 26, 2015 , ... PRMA Plastic Surgery ... 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! , “What ... up every day excited to rebuild lives and it’s an honor to have served ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer ... classically-influenced trailer titles work with any font, giving users limitless opportunities to stylize ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor of ... server to improve system efficiency and reliability. , The new Q-Suite 6 platform is ... the system avoids locking itself into a specific piece of software for many key ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... --> adds "Global Repaglinide ... "Investigation Report on China Repaglinide Market, ... forecasts data and information to its ... . --> ...
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the European Cell Surface Marker Testing ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology: